Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
N-acetylcysteine for therapy-resistant tobacco use disorder: A pilot study
Redox Report, Volume 20, No. 5, Year 2015
Notification
URL copied to clipboard!
Description
N-Acetylcysteine (NAC) may have efficacy in treating tobacco use disorder (TUD) by reducing craving and smoking reward. This study examines whether treatment with NAC may have a clinical efficacy in the treatment of TUD. Methods: A 12-week double blind randomized controlled trial was conducted to compare the clinical efficacy of NAC 3 g/day versus placebo. We recruited 34 outpatients with therapy resistant TUD concurrently treated with smoking-focused group behavioral therapy. Participants had assessments of daily cigarette use (primary outcome), exhaled carbon monoxide (COEXH) (secondary outcome), and quit rates as defined by COEXH<6 ppm. Depression was measured with the Hamilton Depression Rating Scale (HDRS). Data were analyzed using conventional and modified intention-to-treat endpoint analyses. Results: NAC treatment significantly reduced the daily number of cigarettes used (A mean±SD = -10.9 ± 7.9 in the NAC-treated versus -3.2 ± 6.1 in the placebo group) and COEXH (A mean± SD = -10.4 ± 8.6 ppm in the NAC-treated versus -1.5 ± 4.5 ppm in the placebo group); 47.1% of those treated with NAC versus 21.4% of placebo-treated patients were able to quit smoking as defined by COEXH<6 ppm. NAC treatment significantly reduced the HDRS score in patients with tobacco use disorder. Conclusions: These data show that treatment with NAC may have a clinical efficacy in TUD. NAC combined with appropriate psychotherapy appears to be an efficient treatment option for TUD. © W. S. Maney & Son Ltd 2015.
Authors & Co-Authors
Maes, Michael H.J.
Australia, Geelong
Deakin University
Thailand, Bangkok
Chulalongkorn University
Brazil, Londrina
Universidade Estadual de Londrina
Barbosa, Décio Sabbatini
Brazil, Londrina
Universidade Estadual de Londrina
Dodd, Seetal M.
Australia, Geelong
Deakin University
Australia, Melbourne
University of Melbourne
Berk, Michael
Australia, Geelong
Deakin University
Australia, Melbourne
University of Melbourne
Australia, Melbourne
Orygen Youth Health
Australia, Geelong
Barwon Health
Statistics
Citations: 63
Authors: 4
Affiliations: 6
Identifiers
Doi:
10.1179/1351000215Y.0000000004
ISSN:
13510002
Research Areas
Disability
Environmental
Mental Health
Substance Abuse
Study Approach
Quantitative